Search company, investor...

Compare Deciphera Pharmaceuticals vs KeyNeurotek Pharmaceuticals

Customers evaluate the quality of Deciphera Pharmaceuticals's products using the following success metrics.

Overview

Deciphera Pharmaceuticals is based in United States

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Its small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. The company uses their deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a "switched off' or inactivated conformation. These therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. This platform has been used to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their response to treatment.

KeyNeurotek Pharmaceuticals is based in Germany

KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.

Demo Video

Demo not available because Deciphera Pharmaceuticals has not claimed their profile.

Work for Deciphera Pharmaceuticals? Show off your product.

Demo not available because KeyNeurotek Pharmaceuticals has not claimed their profile.

Work for KeyNeurotek Pharmaceuticals? Show off your product.

Leadership

Thomas P Kelly (Chief Financial Officer)

See all 5 people

Frank Striggow (Chief Executive Officer)

See all 3 people

Funding

Deciphera Pharmaceuticals last raised $127.5M on 9/28/2017.
KeyNeurotek Pharmaceuticals last raised $10.9M on 4/10/2009.

Investors

New Leaf Venture Partners, Viking Global Investors

See all 5 investors

IBG Beteiligungsgesellschaft, Deutsche Venture Capital

See all 3 investors

Product

Benefits

Products

Customers

Known Partners

Why They Buy

Information not available because Deciphera Pharmaceuticals has not claimed their profile.

Work for Deciphera Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for Deciphera Pharmaceuticals?

Claim your profile now.

Information not available because KeyNeurotek Pharmaceuticals has not claimed their profile.

Work for KeyNeurotek Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for KeyNeurotek Pharmaceuticals?

Claim your profile now.